Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Dana-Farber Cancer Institute, Stanford University, Memorial Sloan Kettering Cancer Center, Brown University, Stanford Medicine, University of North Carolina at Chapel Hill, Abramson Cancer Center, University of Pennsylvania
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890168660